Promethazine HCl Rectal Suppositories Rx
Generic Name and Formulations:
Promethazine HCl 12.5mg, 25mg, 50mg.
Various generic manufacturers
Indications for Promethazine HCl Rectal Suppositories:
Motion sickness. Perioperative nausea & vomiting.
Motion sickness: 25mg 30–60mins before travel; may repeat in 8–12hrs; maintenance 25mg twice daily. Perioperative nausea & vomiting: 25mg; may give additional doses of 12.5–25mg at 4–6hr intervals.
<2yrs: see Contraindications. Motion sickness: ≥2yrs: 12.5–25mg twice daily. Perioperative nausea & vomiting: 0.5mg/lb or 25mg; may give additional doses of 12.5–25mg or 0.5mg/lb at 4–6hr intervals.
Children <2yrs. Dehydrated or ill children (esp. Reye's syndrome). History of sleep apnea. Asthma and lower respiratory disorders. Uncomplicated nausea in children.
Glaucoma. GI or urinary obstruction. Cardiovascular or liver disease. Seizure disorders. Peptic ulcer. Bone marrow depression. Elderly. Children ≥2yrs. Pregnancy (Cat.C). Nursing mothers: not recommended.
Potentiates CNS depression with alcohol, other CNS depressants. Caution with MAOIs. May alter hCG pregnancy test results.
Drowsiness, lowered seizure threshold, cholestatic jaundice, anticholinergic and extrapyramidal effects, photosensitivity, hypo- or hypertension, rash, blood dyscrasias, nausea, neonatal platelet abnormalities; children: respiratory depression (may be fatal).
Formerly known under the brand names Phenergan (tabs, supps); Promethacon (supps).
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Canagliflozin Trial for T2D With CKD Stopped Early Due to Positive Results
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- Risk for Hypoglycemia During Titration With Insulin Glargine 100 U/mL in T2D
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Effect of SGLT2 Inhibitors on Heart Failure-Related Hospitalization, Below-Knee Amputation
- Nutraceuticals Containing Equol May Be Effective for Postmenopausal Symptoms
- Conservative Monitoring Strategy for Non-Functioning Pituitary Adenomas Evaluated
- FDA: Some Rx Drugs May Become Available Without Seeing a Doctor
- PM2.5 Contributes to Burden of Diabetes Mellitus Globally